Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Jul 11:13:2305-2330.
doi: 10.2147/DDDT.S204974. eCollection 2019.

Efficacy and safety of cyclosporine A in the treatment of idiopathic membranous nephropathy in an Asian population

Shujun Lin  1 , Hong-Yan Li  2 , Tianbiao Zhou  1 , Wenshan Lin  1
Affiliations
Meta-Analysis

Efficacy and safety of cyclosporine A in the treatment of idiopathic membranous nephropathy in an Asian population

Shujun Lin et al. Drug Des Devel Ther. .

Abstract

Introduction: The efficacy of cyclosporine A (CsA) in the treatment of idiopathic membranous nephropathy (IMN) is unclear. This meta-analysis was conducted to assess the efficacy and the safety of CsA in the treatment of IMN in Asians.

Methods: We searched the Pubmed, China Biomedical Database, CNKI, Wanfang Data, VIP, and EMBASE (November 30, 2018) systematically to identify the appropriate randomized controlled trials (RCTs) reporting the efficacy and the safety of CsA and glucocorticoid (GC) treatment vs other immunosuppressants and GC on patients with IMN in Asian populations.

Results: The CsA treated group entered complete remission (CR) faster (3 months) than a cyclophosphamide (CTX) group. While the CsA group lower inefficacy rates and higher total remission (TR, CR, or partial remission) than the CTX group in the total treatment (3 months, 6 months, and 12 months), it had a higher relapse rate. As for the CsA group vs the tacrolimus (TAC) group, the TAC had a significant effect in increasing the CR and the TR, with decreased no remission. With the therapeutic regimens of CsA+GC vs CTX+GC, the CsA exhibited better efficacy in lowering the proteinuria levels only at 12 months, not at 3 months or 6 months. Severe events like leucopenia, hemorrhagic cystitis, and alopecia were observed in the CTX group. Gingival hyperplasia, hirsutism, and elevated blood pressure were reported only in the CsA group. Gastrointestinal syndrome, liver function lesion, happened more frequently in the CTX group, and elevated uric acid was more common in the CsA group.

Conclusions: In brief, the CsA has better efficacy than the CTX group in the Asian population, with mild adverse effects but higher relapse rates in short-term treatment.

Keywords: cyclophosphamide; cyclosporine A; idiopathic membranous nephropathy; mycophenolate mofetil; tacrolimus.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
The effect of CsA+GC vs CTX+GC on CR in patients with IMN in Asian populations. Abbreviations: CsA, cyclosporine A; CTX, cyclophosphamide; GC, glucocorticoid; CR, complete remission; IMN, idiopathic membranous nephropathy.
Figure 2
Figure 2
The effect of CsA+GC vs CTX+GC on TR in patients with IMN in Asian populations. Abbreviations: CsA, cyclosporine A; CTX, cyclophosphamide; GC, glucocorticoid; TR, total remission; IMN, idiopathic membranous nephropathy.
Figure 3
Figure 3
The effect of CsA+GC vs CTX+GC on proteinuria in patients with IMN in Asian populations. Abbreviations: CsA, cyclosporine A; CTX, cyclophosphamide; GC, glucocorticoid; IMN, idiopathic membranous nephropathy.
Figure 4
Figure 4
The effect of CsA+GC vs CTX+GC on serum albumin in patients with IMN in Asian populations. Abbreviations: CsA, cyclosporine A; CTX, cyclophosphamide; GC, glucocorticoid; IMN, idiopathic membranous nephropathy.
See this image and copyright information in PMC

References

    1. Zeng C, Chen H, Wang R, et al. Etiology and clinical characteristics of membranous nephropathy in Chinese patients. Am J Kidney Dis. 2008;52(4):691–698. doi:10.1053/j.ajkd.2008.06.006 - DOI - PubMed
    1. Alfaadhel T, Cattran D. Management of membranous nephropathy in Western countries. Kidney Dis (Basel). 2015;1(2):126–137. doi:10.1159/000437287 - DOI - PMC - PubMed
    1. Polanco N, Gutierrez E, Covarsi A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol. 2010;21(4):697–704. doi:10.1681/ASN.2009080861 - DOI - PMC - PubMed
    1. Quaglia M, Stratta P. Idiopathic membranous nephropathy: management strategies. Drugs. 2009;69(10):1303–1317. doi:10.2165/00003495-200969100-00002 - DOI - PubMed
    1. Daniel C. Management of membranous nephropathy: when and what for treatment. J Am Soc Nephrol. 2005;16(5):1188–1194. doi:10.1681/ASN.2005010028 - DOI - PubMed

Publication types